Anti-tumor effects of interferon-beta cell therapy in murine model of melanoma
Purpose: Recombinant interferon beta (IFN-β) has been used for a treatment of cancers. However, the efficacy of recombinant IFN-β is limited because of its short half-life and side effects. To overcome these problems, we focused on the efficacy of cell-based therapy (cell therapy) using IFN-β-producing cells in the treatment of melanoma.
Methods: IFN-β-producing therapeutic cells were constructed by gene transduction using retrovirus vector. Anti-tumor effects of the cell therapy were investigated by a murine melanoma model.
Results: IFN-β cell therapy significantly suppressed the proliferation of B16 melanoma in vitro and the growth of B16-derived tumor in vivo, accompanied with the activation of natural killer (NK) cells. IFN-β cell therapy did not show any systemic side-effects concerning hepatic dysfunction and bone marrow suppression.
Conclusion: IFN-β cell therapy could be a candidate as a novel cancer treatment.
Uddin S, Platanias L. Mechanisms of Type-I interferon signal transduction. Journal of Biochemistry and molecular biology. 2004;37(6):635641.
Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984;2(4):336–52.
Sayers TJ, Wiltrout TA, McCormick K, et al. Antitumor effects of alpha-interferon and gamma-interferon on a murine renal cancer (Renca) in vitro and in vivo. Cancer Res. 1990;50(17):5414–20.
Sakurai M, Iigo M, Sasaki Y, et al. [Direct and indirect antitumor effect of murine recombinant interferons].Gan To Kagaku Ryoho. 1987;14(3 Pt 2):889–95.
Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–86.
Ralph P, Nakoinz I, Rennick D. Role of interleukin 2, interleukin 4, and alpha, beta, and gamma interferon in stimulating macrophage antibody-dependent tumoricidal activity. J Exp Med. 1988;167(2):712–7.
Gidlund M, Orn A, Wigzell H, et al. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature. 1978;273(5665):759–61.
Fine HA, Wen PY, Robertson M, et al. A phase I trial of a new recombinant human beta-interferon (BG9015) for the treatment of patients with recurrent gliomas. Clin Cancer Res. 1997;3(3):381–7.
Hsu C-SS, Chao Y-CC, Lin HH, et al. Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma. Sci Rep. 2015;5:9954.
Borden EC, Jacobs B, Hollovary E, et al. Gene regulatory and clinical effects of interferon β in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res. 2011;31(5):433–40.
Compagna R, Amato B, Massa S, et al. Cell Therapy in Patients with Critical Limb Ischemia. Stem Cells Int. 2015;2015:931420.
Fisher SA, Doree C, Mathur A, et al. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116(8):1361–77.
Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res. 2015;116(9):1561–78.
Murakami Y, Akahoshi T, Kawai S, et al. Antiinflammatory effect of retrovirally transfected interleukin-10 on monosodium urate monohydrate crystal-induced acute inflammation in murine air pouches. Arthritis Rheum. 2002;46(9):2504–13.
Kosaka S, Tamauchi H, Terashima M, et al. IL-10 controls Th2-type cytokine production and eosinophil infiltration in a mouse model of allergic airway inflammation. Immunobiology. 2011;216(7):811–20.
Watkins SK, Zhu Z, Watkins KE, et al. Isolation of immune cells from primary tumors. J Vis Exp. 2012;(64):e3952.
Yoshida J, Mizuno M, Wakabayashi T. Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004;95(11):858–65.
Ryuke Y, Mizuno M, Natsume A, et al. Growth inhibition of subcutaneous mouse melanoma and induction of natural killer cells by liposome-mediated interferon-beta gene therapy. Melanoma Res. 2003;13(4):349–56.
McCarty MF, Bielenberg D, Donawho C, et al. Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis. 2002;19(7):609–15.
Takano S, Ishikawa E, Matsuda M, et al. Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10. Int J Oncol. 2014;45(5):1837–46.
Kobayashi H, Nobeyama Y, Nakagawa H. Tumor-suppressive effects of natural-type interferon-β through CXCL10 in melanoma. Biochem Biophys Res Commun. 2015;464(2):416–21.
Antonicelli F, Lorin J, Kurdykowski S, et al. CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol. 2011;164(4):720–8.
Schneble EJ, Yu X, Wagner TE, et al. Novel dendritic cell-based vaccination in late stage melanoma. Hum Vaccin Immunother. 2014;10(11):3132–8.
Karimi K, Karimi Y, Chan J, et al. Type I IFN signaling on dendritic cells is required for NK cell-mediated anti-tumor immunity. Innate Immun. 2015;21(6):626–34.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.